Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Number needed to treat in COPD: exacerbations versus pneumonias.

Suissa S.

Thorax. 2013 Jun;68(6):540-3. doi: 10.1136/thoraxjnl-2012-202709. Epub 2012 Nov 2. Review.

PMID:
23125170
2.

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.

Welsh EJ, Cates CJ, Poole P.

Cochrane Database Syst Rev. 2010 May 12;(5):CD007891. doi: 10.1002/14651858.CD007891.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;5:CD007891.

PMID:
20464758
3.

Number needed to treat in COPD: exacerbations versus pneumonias.

Keene ON, Anzueto A, Ferguson GT, Calverley PM.

Thorax. 2013 Sep;68(9):882. doi: 10.1136/thoraxjnl-2013-203403. Epub 2013 Mar 15. No abstract available.

PMID:
23503625
4.

Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease.

Nannini L, Cates CJ, Lasserson TJ, Poole P.

Cochrane Database Syst Rev. 2004;(3):CD003794. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD003794.

PMID:
15266502
5.

Author's response to letter on number needed to treat in COPD: exacerbations versus pneumonias.

Suissa S.

Thorax. 2013 Sep;68(9):882-3. doi: 10.1136/thoraxjnl-2013-203461. Epub 2013 Mar 22. No abstract available.

PMID:
23935172
6.

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):19-26. Epub 2007 Oct 4.

PMID:
17916806
7.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators.

N Engl J Med. 2007 Feb 22;356(8):775-89.

8.
10.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

11.

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.

Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.

Respir Med. 2008 Aug;102(8):1099-108. doi: 10.1016/j.rmed.2008.04.019. Epub 2008 Jul 9.

12.

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Yawn BP, Raphiou I, Hurley JS, Dalal AA.

Int J Chron Obstruct Pulmon Dis. 2010 Jun 3;5:165-78. Review.

13.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
14.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Karner C, Cates CJ, Evans DJ.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007033. doi: 10.1002/14651858.CD007033.pub3. Review.

PMID:
22161409
15.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Evans DJ, Karner C, Cates CJ.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007033. doi: 10.1002/14651858.CD007033.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD007033.

PMID:
21975759
16.

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.

Nannini L, Lasserson TJ, Poole P.

Cochrane Database Syst Rev. 2003;(4):CD003794. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD003794.

PMID:
14583994
17.

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.

Halpin DM, Gray J, Edwards SJ, Morais J, Singh D.

Int J Clin Pract. 2011 Jul;65(7):764-74. doi: 10.1111/j.1742-1241.2011.02685.x. Review.

PMID:
21676119
18.
19.

Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.

Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.

Respir Med. 2013 Apr;107(4):542-9. doi: 10.1016/j.rmed.2012.12.020. Epub 2013 Jan 20.

20.

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Kardos P, Wencker M, Glaab T, Vogelmeier C.

Am J Respir Crit Care Med. 2007 Jan 15;175(2):144-9. Epub 2006 Oct 19.

PMID:
17053207
Items per page

Supplemental Content

Write to the Help Desk